SCHEMBL5358202

SCHEMBL5358202

CCOC(=O)c1[nH]c(C=C2C(=O)Nc3ccc(Br)c(C)c32)c(C(=O)OC)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.45
FGFR1 P11362 2/20 0.45
ABL1 P00519 1/20 0.45
RET P07949 1/20 0.45
FLT3 P36888 1/20 0.45
ALK Q9UM73 1/20 0.45
ALDH1A1 P00352 2/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
KDR P35968 3/20 0.41
GSK3B P49841 1/20 0.39
EGFR P00533 2/20 0.38
PDGFRA P16234 1/20 0.38
AURKA O14965 1/20 0.37
RAF1 P04049 1/20 0.37
HPGD P15428 2/20 0.37
CSF1R P07333 1/20 0.37
RAB9A P51151 3/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7136169 0.85 ALDH1A1 (0.44) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5368918 0.82 PDGFRB (0.66) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5991909 0.81 ABL1 (0.45) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5358435 0.80 KDR (0.53) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5365038 0.79 AURKA (0.36) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5988621 0.78 KDR (0.52) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5990240 0.78 PDGFRB (0.51) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5989490 0.78 RET (0.48) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5368395 0.78 AURKA (0.39) PDGFRBFGFR1ABL1RETFLT3
SCHEMBL5362226 0.77 SRC (0.53) PDGFRBFGFR1ABL1RETFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK PDGFRB 52/4885FGFR1 112/4885ABL1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.